Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction

被引:279
作者
Alizadeh, M
Bernard, M
Danic, B
Dauriac, C
Birebent, B
Lapart, C
Lamy, T
Le Prisé, PY
Beauplet, A
Bories, D
Semana, G
Quelvennec, E
机构
[1] Univ Rennes 2, Fac Med, Immunol Lab, UPRESEA 1257,IFR 97, F-35043 Rennes, France
[2] Estab Francais Sang Bretagne, Rennes, France
[3] CHRU Rennes, Serv Hematol clin, Rennes, France
[4] Hop Henri Mondor, Hematol Lab, F-94010 Creteil, France
关键词
D O I
10.1182/blood.V99.12.4618
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have developed a real-time quantitative polymerase chain reaction (PCR) assay using TaqMan technology (Applied Biosystems, Foster City CA) for monitoring donor cell engraftment in allogenic hematopoietic stem cell transplant recipients. For this purpose, we selected 19 specific sequence polymorphisms belonging to 11 human biallelic loci located on 9 different chromosomes. Using a set of specially designed primers and fluorogenic probes, we evaluated the 19 markers' informativity on a panel of 126 DNA samples from 63 recipient/donor pairs. In more than 90% of these pairs, discrimination between recipient and donor genetic profile was possible. By using serial dilutions of mixed DNAs, we evaluated the linearity and sensitivity of the method. A linear correlation with r higher than 0.98 and a sensitivity of 0.1% proved reproducible. Fluorescent-based PCR of short tandem repeats (STR-PCR) and real-time PCR chimerism assay were compared with a panel of artificial cell mixtures. The main advantage of the real-time PCR method over STR-PCR chimerism assays is the absence of PCR competition and plateau biases, and results evidenced greater sensitivity and linearity with the real-time PCR method. Furthermore, different samples can be tested in the same PCR run with a final result in fewer than 48 hours. Finally, we prospectively analyzed patients who received allografts and present 4 different clinical situations that illustrate the informativity level of our method. In conclusion, this new assay provides an accurate quantitative assessment of mixed chimerism that can be useful In guiding early implementation of additional treatments in hematopoietic stem cell transplantation. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:4618 / 4625
页数:8
相关论文
共 33 条
[1]   Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT [J].
Bader, P ;
Beck, J ;
Frey, A ;
Schlegel, PG ;
Hebarth, H ;
Handgretinger, R ;
Einsele, H ;
Niemeyer, C ;
Benda, N ;
Faul, C ;
Kanz, L ;
Niethammer, D ;
Klingebiel, T .
BONE MARROW TRANSPLANTATION, 1998, 21 (05) :487-495
[2]   Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children [J].
Bader, P ;
Klingebiel, T ;
Schaudt, A ;
Theurer-Mainka, U ;
Handgretinger, R ;
Lang, P ;
Niethammer, D ;
Beck, JF .
LEUKEMIA, 1999, 13 (12) :2079-2086
[3]  
Bernasconi P, 1997, LEUKEMIA, V11, P1989
[4]   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses [J].
Childs, R ;
Clave, E ;
Contentin, N ;
Jayasekera, D ;
Hensel, N ;
Leitman, S ;
Read, EJ ;
Carter, C ;
Bahceci, E ;
Young, NS ;
Barrett, AJ .
BLOOD, 1999, 94 (09) :3234-3241
[5]   Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection [J].
Dubovsky, J ;
Daxberger, H ;
Fritsch, G ;
Printz, D ;
Peters, C ;
Matthes, S ;
Gadner, H ;
Lion, T .
LEUKEMIA, 1999, 13 (12) :2060-2069
[6]   GENETIC-VARIATION AT 5 TRIMERIC AND TETRAMERIC TANDEM REPEAT LOCI IN 4 HUMAN-POPULATION GROUPS [J].
EDWARDS, A ;
HAMMOND, HA ;
JIN, L ;
CASKEY, CT ;
CHAKRABORTY, R .
GENOMICS, 1992, 12 (02) :241-253
[7]  
Elmaagacli AH, 1996, BONE MARROW TRANSPL, V18, P397
[8]   Prediction and reversion of post-transplant relapse in patients with chronic myeloid leukemia using mixed chimerism and residual disease detection and adoptive immunotherapy [J].
Formánková, R ;
Honzátková, L ;
Moravcová, J ;
Sieglová, Z ;
Dvoráková, R ;
Nádvorníková, S ;
Vítek, A ;
Lukásová, M ;
Stary, J ;
Brdicka, R .
LEUKEMIA RESEARCH, 2000, 24 (04) :339-347
[9]   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy [J].
Giralt, S ;
Estey, E ;
Albitar, M ;
vanBesien, K ;
Rondon, G ;
Anderlini, P ;
OBrien, S ;
Khouri, I ;
Gajewski, J ;
Mehra, R ;
Claxton, D ;
Andersson, B ;
Beran, M ;
Przepiorka, D ;
Koller, C ;
Kornblau, S ;
Korbling, M ;
Keating, M ;
Kantarjian, H ;
Champlin, R .
BLOOD, 1997, 89 (12) :4531-4536
[10]  
Gyger M, 1998, EXP HEMATOL, V26, P426